Page 4 - Fluticasone Propionate News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Vectura : highlights update made by Hikma on launch of generic Advair Diskus® Published21/04/2021 Read more

Vectura : highlights update made by Hikma on launch of generic Advair Diskus® Published21/04/2021 Read more
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Glaxosmithkline advair diskusAdvair diskusVectura groupHikma pharmaceuticalsAbbreviated new drug applicationFluticasone propionateSalmeterol inhalation powderஹிக்மா மருந்துகள்

Hikma resumes launch of generic Advair Diskus®

Hikma resumes launch of generic Advair Diskus® News provided by Share this article Share this article LONDON, April 20, 2021 /PRNewswire/ Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that it has resumed the launch of its generic version of GlaxoSmithKline s Advair Diskus ®1 in the US following US FDA approval of an amendment Hikma submitted to its Abbreviated New Drug Application in January 2021. The amendment reflected enhanced packaging controls to meet new industry standards adopted since the initial submission of its ANDA. Hikma will immediately resume launch activities of its generic product for Advair Diskus ® (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in the US.

United arab emiratesUnited statesUnited kingdomCity ofSteve weissSusan ringdalGlaxosmithkline advair diskusSiggi olafssonDavid belianAdvair diskusCharles armitstead claire sciclunaUs communicationsPublic affairsGlobal affairsHikma pharmaceuticalsHikma pharmaceuticals united states inc

Hikma launches generic Advair Diskus® following FDA approval

Hikma launches generic Advair Diskus® following FDA approval News provided by Share this article Share this article LONDON, Dec. 17, 2020 /PRNewswire/ Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it has received FDA approval for and launched its generic version of GlaxoSmithKline s Advair Diskus ®1 (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in the US. Hikma worked with Vectura Group, a UK based provider of innovative inhaler drug delivery solutions, to develop the proprietary dry powder inhaler and formulation technology. According to IQVIA, US sales of Fluticasone Propionate and Salmeterol Inhalation Powder USP, 100mcg/50mcg and 250mcg/50mcg, were approximately $2 billion in the 12 months ending September 2020.

United arab emiratesUnited statesUnited kingdomCity ofSteve weissCharles armitstead camilla cunninghamGlaxosmithkline advair diskusSusan ringdalSiggi olafssonDavid belianAdvair diskusVectura groupGlobal affairsWard columbus incHikma pharmaceuticals united states incUs communications

Investegate |Hikma Pharmaceutical Announcements | Hikma Pharmaceutical: Hikma launches generic Advair Diskus

London, 17 December 2020 - Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, annou nces it has received FDA approval for and launched its generic version of GlaxoSmithKline s Advair Diskus ®1 (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in the US. Hikma worked with Vectura Group, a UK based provider of innovative inhaler drug delivery solutions, to develop the proprietary dry powder inhaler and formulation technology. According to IQVIA, US sales of Fluticasone Propionate and Salmeterol Inhalation Powder USP, 100mcg/50mcg and 250mcg/50mcg, were approximately $2 billion in the 12 months ending September 2020. Siggi Olafsson, Chief Executive Officer of Hikma, said The approval of our generic version of Advair Diskus

United arab emiratesUnited statesUnited kingdomCity ofSteve weissCharles armitstead camilla cunninghamGlaxosmithkline advair diskusSusan ringdalSiggi olafssonDavid belianAdvair diskusVectura groupGlobal affairsWard columbus incHikma pharmaceuticals united states incUs communications